Category: Federal Forum Posters
Purpose: In the United States, twelve-month and lifetime prevalence of alcohol use disorder are 13.9% and 29.1%, respectively. Unfortunately, in veterans, this number is significantly higher. In a study done to assess the burden of alcohol use disorder on veterans, the prevalence of twelve-month and lifetime alcohol use disorder was 14.8 % and 42.2%, respectively. Alcohol use disorder can cause significant morbidity and mortality and treatment is often plagued by medication discontinuation or relapse. The objective of this study is to assess the efficacy, defined by time to relapse, of long-acting injectable naltrexone use versus oral naltrexone.
Methods: This study will be a retrospective electronic chart review of patients with alcohol use disorder who were treated with long-acting injectable naltrexone or oral naltrexone at a Veteran's Affairs Medical Center from August 1st, 2016 to July 31st, 2018. Patients on oral naltrexone will be randomized to match long-acting injectable naltrexone patients. Pertinent demographic and treatment related information will be collected. The primary outcome assessed is time to relapse. Secondary outcomes include medication possession ratio, three-month treatment outcome, total length of medication therapy, and safety outcomes. All data will be recorded without patient identifiers and maintained confidentiality.
Results: Not applicable
Conclusion: Not applicable
Anne Leighty– PGY1 Pharmacy Resident, Richard L. Roudebush VA Medical Center, Fishers, IN